What is the current Adjuvant Therapy market size?

The Adjuvant Therapy market size is approximately USD 10.2 billion as of 2022.

What is the expected growth forecast for the Adjuvant Therapy market?

The market is expected to grow at a CAGR of 7.8% from 2023 to 2028.

What are the key drivers of the Adjuvant Therapy market?

Increasing cancer incidence and advancing treatment options drive the Adjuvant Therapy market.

What are the major challenges faced by the Adjuvant Therapy market?

High treatment costs and limited awareness hinder the Adjuvant Therapy market growth.

Which regions are the leaders in the Adjuvant Therapy market?

North America and Europe are the leading regions in the Adjuvant Therapy market.

Who are the top companies in the Adjuvant Therapy market?

Pfizer, Roche, and Merck are prominent players in the Adjuvant Therapy market.

What are the future opportunities in the Adjuvant Therapy market?

Emerging markets and innovative therapies offer future outlook opportunities.

How does technology impact the Adjuvant Therapy market?

Advances in precision medicine and digital health transform the Adjuvant Therapy market.

What is the regulatory landscape for the Adjuvant Therapy market?

Stringent regulations and approvals from FDA and EMA shape the Adjuvant Therapy market.

What is the future outlook for the Adjuvant Therapy market size?

The Adjuvant Therapy market size is expected to reach USD 15.6 billion by 2028.

Adjuvant Therapy Industry Trends & Competitive Analysis 2033

Adjuvant Therapy by Application (Hospital, Medical Institution, Others), by Types (Chemotherapy, Radiotherapy, Hormonotherapy, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Adjuvant Therapy Market Size | CAGR 8.2 Forecast 2033

Adjuvant Therapy Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Adjuvant Therapy Market Overview

The Adjuvant Therapy market refers to the use of additional treatments to support primary therapy, enhancing its effectiveness. As a crucial aspect of cancer treatment, the Adjuvant Therapy market size is estimated to be approximately $13.4 billion. The growth outlook for this market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of 7.3% during the forecast period. The industry expansion is driven by increasing cancer incidence, technological advancements, and rising healthcare expenditure. The scope of the Adjuvant Therapy market encompasses various cancer types, including breast, lung, and colorectal cancer, and treatment modalities such as chemotherapy, radiation therapy, and targeted therapy.

Loading chart…

Key forces shaping the Adjuvant Therapy industry include technology shifts towards personalized medicine, regulatory approvals for new treatments, and changing consumer behavior driven by increased awareness about cancer treatment options. The largest region in the Adjuvant Therapy market is North America, while the fastest-growing region is Asia-Pacific. The market growth is driven by macro drivers such as increasing cancer incidence, aging population, and growing healthcare expenditure. As the Adjuvant Therapy market continues to evolve, it is essential for stakeholders to stay informed about the latest trends, opportunities, and challenges to make strategic decisions and drive business growth.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	24.05 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck (Merck); Bayer (Bayer); Johnson & Johnson (Johnson & Johnson); AstraZeneca (AstraZeneca); Mylan (Viatris (formerly Mylan)); AbbVie (AbbVie); Novartis (Novartis)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Adjuvant Therapy market is poised for significant growth, driven by factors such as increasing cancer incidence rates and advancements in medical technology. The Adjuvant Therapy market size is expected to expand rapidly, with a growth forecast that indicates a substantial increase in revenue over the next few years.

Growth Drivers2 items

Advances in immunotherapy and targeted therapies are enhancing treatment outcomes, leading to increased adoption of Adjuvant Therapy, thereby driving the Adjuvant Therapy market size

Rising cancer awareness and growing demand for effective treatment options are fueling the growth of the Adjuvant Therapy market, with the growth forecast indicating a significant surge in demand

Restraints2 items

High costs associated with Adjuvant Therapy treatments and limited reimbursement options are hindering market growth, affecting the overall Adjuvant Therapy market size

Stringent regulatory requirements and time-consuming approval processes for new therapies are restricting the entry of new players in the Adjuvant Therapy market

Opportunities2 items

Emerging markets and increasing healthcare expenditure in developing economies are presenting new opportunities for Adjuvant Therapy market players, driving the growth forecast

Collaborations and partnerships between pharmaceutical companies and research institutions are facilitating the development of innovative Adjuvant Therapy treatments

Challenges2 items

Managing side effects and ensuring patient safety are significant challenges in Adjuvant Therapy, impacting the overall Adjuvant Therapy market size and growth forecast

Staying ahead of the competition and adapting to rapidly evolving treatment landscapes are key challenges for companies operating in the Adjuvant Therapy market

Market Segmentation

Loading chart…

The Application segment of the Adjuvant Therapy market is a crucial aspect of Adjuvant Therapy segmentation. This segment is divided into various subtypes, including breast cancer, colorectal cancer, and lung cancer, among others. Each subtype contributes significantly to the overall Adjuvant Therapy market size, with breast cancer being the largest contributor due to the high prevalence of the disease. Understanding the application segment is essential for market players to develop targeted therapies and strategies.

The Types segment of the Adjuvant Therapy market plays a vital role in shaping the industry's landscape. This segment includes subtypes such as chemotherapy, hormone therapy, and targeted therapy, among others. Chemotherapy is the most widely used type of adjuvant therapy, accounting for a significant share of the market. The types segment is critical in determining the market taxonomy of Adjuvant Therapy, as it helps in identifying the most effective treatment options for various types of cancers.

Adjuvant Therapy Segmentation Breakdown9 items

Application

Hospital

Medical Institution

Others

Types

Chemotherapy

Radiotherapy

Hormonotherapy

Others

Regional Insights

Loading chart…

The Adjuvant Therapy market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The Asia Pacific region is expected to be the fastest-growing, driven by increasing adoption of adjuvant therapy, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include a strong regulatory framework, increasing adoption of adjuvant therapy, and a large patient population. The Asia Pacific region is driven by a growing middle-class population, increasing healthcare expenditure, and a rising prevalence of chronic diseases.

Latin America and Middle East & Africa are expected to experience moderate growth, driven by improving infrastructure, increasing adoption of adjuvant therapy, and growing demand for cancer treatment options. The regional forecast indicates that these regions will play an increasingly important role in the global Adjuvant Therapy market.

Competitive Landscape

The Adjuvant Therapy market is moderately consolidated, driven by a mix of global players and local companies. The Adjuvant Therapy competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and strategic partnerships to maintain their market position, while local companies concentrate on regional expansion and cost-effective solutions.

Companies in the Adjuvant Therapy market employ various strategies to differentiate themselves, including mergers and acquisitions, partnerships, product launches, and research and development. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must focus on technology, service model, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

Merck: regional expansion

Bayer: innovation pipeline

Johnson & Johnson: premium pricing

AstraZeneca: local manufacturing

Viatris: OEM tie-ups

AbbVie: vertical integration

Key Adjuvant Therapy Companies7 items

Merck (Merck)

Bayer (Bayer)

Johnson & Johnson (Johnson & Johnson)

AstraZeneca (AstraZeneca)

Mylan (Viatris (formerly Mylan))

AbbVie (AbbVie)

Novartis (Novartis)

Market Ecosystem

The Adjuvant Therapy ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and delivery of adjuvant therapies, with each segment influencing the overall efficiency and effectiveness of the ecosystem. Understanding the Adjuvant Therapy ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material suppliers — providing essential components

Technology providers — developing adjuvant therapy solutions

OEMs/manufacturers — producing adjuvant therapies

Distributors/channel partners — facilitating delivery to end users

Service providers/after-sales — offering support and maintenance services

Regulators/standards bodies — establishing guidelines and approvals

End users/buyers — receiving and administering adjuvant therapies

The flow of value within the Adjuvant Therapy ecosystem is influenced by control points, such as regulatory approvals and reimbursement policies, which can impact adoption rates. Dependency risks, including input constraints and standards, can also affect the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can create bottlenecks, while regional differences in healthcare infrastructure and policies can lead to variations in the ecosystem across different regions.

Recent Industry Insights

The Adjuvant Therapy industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between pharmaceutical companies and research institutions have led to the discovery of new adjuvant therapies, enhancing treatment outcomes for various diseases. Notable mergers and acquisitions have also taken place, resulting in the expansion of product portfolios and increased investment in research and development. Furthermore, regulatory changes have facilitated the approval of innovative adjuvant therapies, making them more accessible to patients. A shift in consumer trends has also been observed, with a growing emphasis on personalized medicine and targeted therapies. Additionally, funding rounds and expansions have enabled companies to explore new technologies and develop more effective adjuvant therapies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Adjuvant Therapy market. The market attractiveness is high due to the increasing prevalence of cancer and the growing demand for effective treatments. The competitive intensity is moderate, with several key players competing for market share. The long-term outlook for the Adjuvant Therapy market outlook is positive, driven by advancements in technology and innovation. The innovation landscape is dynamic, with ongoing research and development of new therapies.

The demand-supply balance is stable, with a steady supply of adjuvant therapies meeting the growing demand. However, key risk factors such as regulatory changes and patent expirations may impact the market. Overall, the Adjuvant Therapy market is expected to experience steady growth, driven by the increasing need for effective cancer treatments.

11 items

1. Executive Summary

2. Adjuvant Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Adjuvant Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Adjuvant Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Medical Institution

6.1.3. Others

6.2. Global Adjuvant Therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Chemotherapy

6.2.2. Radiotherapy

6.2.3. Hormonotherapy

6.2.4. Others

6.3. Global Adjuvant Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Adjuvant Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Adjuvant Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Adjuvant Therapy Market Competition by Key Manufacturers

8.1. Global Adjuvant Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Adjuvant Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck (Merck)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer (Bayer)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Johnson & Johnson (Johnson & Johnson)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. AstraZeneca (AstraZeneca)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Mylan (Viatris (formerly Mylan))

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. AbbVie (AbbVie)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Novartis (Novartis)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Adjuvant Therapy Market

Figure 4: Global Adjuvant Therapy Market: Drivers

Figure 5: Global Adjuvant Therapy Market: Challenges

Figure 6: Global Adjuvant Therapy Market: Trends

Figure 7: Global Adjuvant Therapy Market: Opportunity

Figure 8: Global Adjuvant Therapy Market: Restraint

Figure 9: Global Adjuvant Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Adjuvant Therapy Market Value (USD Million) By Region

Figure 15: Global Adjuvant Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Adjuvant Therapy Market Value (USD Million) By Region

Figure 23: Global Adjuvant Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global Adjuvant Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Adjuvant Therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Adjuvant Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Adjuvant Therapy Market Value (USD Million) By Region

Table 10: Global Adjuvant Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Adjuvant Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Adjuvant Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Adjuvant Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck (Merck) Basic Information And Sales Area

Table 31: Merck (Merck). Products Portfolio

Table 32: Bayer (Bayer) Basic Information And Sales Area

Table 33: Bayer (Bayer). Products Portfolio

Table 34: Johnson & Johnson (Johnson & Johnson) Basic Information And Sales Area

Table 35: Johnson & Johnson (Johnson & Johnson). Products Portfolio

Table 36: AstraZeneca (AstraZeneca) Basic Information And Sales Area

Table 37: AstraZeneca (AstraZeneca). Products Portfolio

Table 38: Mylan (Viatris (formerly Mylan)) Basic Information And Sales Area

Table 39: Mylan (Viatris (formerly Mylan)). Products Portfolio

Table 40: AbbVie (AbbVie) Basic Information And Sales Area

Table 41: AbbVie (AbbVie). Products Portfolio

Table 42: Novartis (Novartis) Basic Information And Sales Area

Table 43: Novartis (Novartis). Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Types

Table 47: Global Market Share (%) By Types (2032)

Table 48: Global Adjuvant Therapy Market Value (USD Million) By Region

Table 49: Global Adjuvant Therapy Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Application

Table 52: North America Market Value (USD Million) (2025-2032) By Types

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Types

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Types

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Adjuvant Therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	24.05 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck (Merck); Bayer (Bayer); Johnson & Johnson (Johnson & Johnson); AstraZeneca (AstraZeneca); Mylan (Viatris (formerly Mylan)); AbbVie (AbbVie); Novartis (Novartis)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options